Future4Care’s Post

In today's evolving healthcare landscape, optimizing treatment adherence is crucial for patient outcomes and commercial success. Leal Health's precision-medicine-based, AI models offer a transformative approach to enhancing your company's tx-adherence capabilities. -**Personalized Patient Engagement**: Utilize AI-powered predictions to identify high-risk patients for non-adherence based on various factors like demographics and treatment history. Tailor NBA-interventions by providing personalized messages, reminders, and support programs based on individual needs. - **Improved Treatment Outcomes**: Proactively mitigate risks by identifying and addressing adherence barriers early on. Enhance the patient experience, leading to improved satisfaction and engagement with their treatment. Minimize treatment interruptions to optimize efficacy. - **Data-Driven Decision Making**: Generate PRO, real-world evidence by collecting and analyzing data on patient behavior and outcomes. This data can help optimize marketing and sales strategies to target receptive patient populations effectively. By harnessing precision medicine AI, you can: - Increase patient retention and enhance treatment outcomes. - Gain a competitive advantage in the market. - Showcase a strong dedication to patient-centric care. Are you prepared to harness the potential of AI-driven precision medicine for your TX-adherence Go-To-Market strategy? Message me to learn more. #Pharmaceuticals #Healthcare #Innovation #DataScience #ai #oncology

The healthcare landscape is shifting, and strategy is more critical than ever. Vizient's 2025 Trends Report highlights key areas: expanding access, leveraging AI and analytics, optimizing Medicare Advantage and driving pharmacy innovation. Access actionable insights designed to help leaders build sustainable, impactful healthcare models.

Real-World Evidence: Transforming Patient Finding in Healthcare One of the biggest challenges in healthcare today is identifying the right patients at the right time—whether for clinical trials, rare diseases, or personalized treatments. Real-World Evidence (RWE) offers a solution by leveraging real-world data (RWD) to find patients faster and more accurately. AI-powered patient-finding solutions that analyze vast amounts of healthcare data in real-time is the solution Data Aggregation & AI: Using AI, diverse data sources (EHRs, claims, patient-reported outcomes) can create precise patient profiles and predict who is most suitable for specific trials or treatments. Precision in Oncology: RWE is already changing oncology by identifying patients who respond best to targeted therapies, accelerating clinical trial enrollment and improving outcomes. Overcoming Challenges: Ensuring patient privacy, address interoperability issues, and reduce bias to create equitable solutions that benefit diverse populations. As we integrate real-time data and scale globally, RWE-powered patient finding will revolutionize healthcare by delivering personalized care faster and more efficiently. How are you leveraging RWE to find the right patients? #RealWorldEvidence #PatientFinding #AIinHealthcare #DataAnalytics #PrecisionMedicine #HealthcareInnovation

We know they are out there……. But wow, are those patients hard to find! With ‘Fall conference season’ well underway I enjoy following here on LinkedIn what is shared, presented, discussed on topics related to patient engagement, decentralisation of clinical trial elements, novel patientcentric endpoints and overall operational optimisation of the clinical development processes. Once we have the patients identified, screened and enrolled there is a lot we can do and are doing in new ways of working. However - the secret of consistantly achieving on-time patient recruitment for each trial has not been revealed. We know the patients exist. How do we find where they live, what they need, what matters most to them? Who and where are the patients who want to and can be enrolled in trials? On Wednesday November 13th, the Dutch ACRO ACRON joins the conference season with the annual symposium on Innovation. This year, Artificial Intelligence and its role in healthcare in general and clinical research specifically will be explored. I look forward to sharing some insights on how AI can be used to win at ‘hide and seek’ and to distinguish between the forest and the trees. How AI is used today to help us select the right sites and secure successful delivery of the clinical trials. Andre Dekker Bart Scheerder Wing Lon Ng Robert Zambon Syneos Health

WELL's strategic partner, HEALWELL AI, has entered into a groundbreaking partnership with Takeda Canada Inc. to support real-world evidence analysis for rare diseases, specifically focusing on patients living with Hereditary Angioedema (HAE). HEALWELL AI's Pentavere will leverage its cutting-edge AI technology to analyze vast amounts of medical data, providing valuable insights into the treatment and management of HAE. This collaboration aims to enhance disease detection, streamline clinical processes, and ultimately improve patient outcomes on a global scale. This partnership will not only harness the power of AI to provide deeper insights into HAE, but also pave the way for advancements in the treatment of other rare diseases. As the largest shareholder of HEALWELL AI, WELL is proud to support and celebrate this significant milestone. Together, we're driving innovation in healthcare and making strides towards a healthier future for all. Read more about this exciting partnership by following the link below. https://ow.ly/W0lK50Sc08f #WELLHealth #HEALWELLAI #AI

The healthcare landscape is shifting, and strategy is more critical than ever. Vizient's 2025 Trends Report highlights key areas: expanding access, leveraging AI and analytics, optimizing Medicare Advantage and driving pharmacy innovation. Access actionable insights designed to help leaders build sustainable, impactful healthcare models.

AI Tackles Rare Diseases! WELL Health Technologies Corp. (TSX: WELL) HEALWELL AI Partners with Takeda Canada Inc. Our AI partner, HEALWELL AI, joins Takeda Canada to use AI for real-world evidence analysis in Hereditary Angioedema (HAE). This collaboration aims to improve HAE detection, treatment, and patient outcomes globally. Read more below. #WELLHealth #HEALWELLAI #AI

It’s a big day for Atropos Health. Congratulations to the entire Atropos team for a successful series B fund raise. This significant milestone is a testament to the company’s innovative vision, relentless dedication, and the remarkable progress in the health care and life science industry. Securing Series B funding is no small feat, and it speaks volumes about the confidence that investors have in Atropos Health’s business model, leadership, and growth potential. This accomplishment not only validates the hard work and commitment of the team but also sets the stage for exciting new opportunities and continued expansion. As Atropos Health embarks on its next phase of growth, I am confident that it will continue to break new ground and achieve even greater success. Their ability to inspire, lead, and innovate is truly commendable, and I look forward to witnessing the impactful advancements and contributions to improve healthcare delivery and accelerate clinical research. Following Atropos Health’s partnership with Arcadia, increasingly they are starting to see their solution emerge as a critical piece of infrastructure for value-based care. Atropos Health is pre-programming content that is organized around top DRGs and Care Management areas. showing "Clinical Evidence and Cost in a single view" which allows you to connect clinical outcomes and cost and quality outcomes.Ask them for a demo.Arcadia #VBC #Valuebasedcare #CareManagement #QualityOutcomes

Helfie AI Appoints Healthcare Industry Leaders Antonin de Fougerolles and Cheryl Buxton ...These appointments herald a pivotal phase in Helfie AI's mission to revolutionise global healthcare access and participation. George Tomeski, Helfie ...https://lnkd.in/eSZeMHUn